Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials

[1]  I. Blake,et al.  Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021. , 2022, MMWR. Morbidity and mortality weekly report.

[2]  John O. Konz,et al.  Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. , 2021, The Journal of infectious diseases.

[3]  John O. Konz,et al.  Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses , 2021, NPJ vaccines.

[4]  John O. Konz,et al.  Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials , 2020, The Lancet.

[5]  K. Badizadegan,et al.  Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain , 2020, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  O. Diop,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[7]  John O. Konz,et al.  Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence , 2020, Cell host & microbe.

[8]  M. Pallansch,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019 , 2019, MMWR. Morbidity and mortality weekly report.

[9]  John O. Konz,et al.  The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study , 2019, The Lancet.

[10]  Paul Chenoweth,et al.  Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine , 2018, The New England journal of medicine.

[11]  Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing. , 2017, Journal of virological methods.

[12]  R. Nielsen,et al.  The Evolutionary Pathway to Virulence of an RNA Virus , 2017, Cell.

[13]  R. Andino,et al.  RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence. , 2016, Cell host & microbe.

[14]  K. Chumakov,et al.  Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines , 2010, Proceedings of the National Academy of Sciences.

[15]  A. Nomoto.  Molecular aspects of poliovirus pathogenesis , 2007, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[16]  J. Meredith,et al.  Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication , 2006, Journal of Virology.

[17]  V. Racaniello.  One hundred years of poliovirus pathogenesis. , 2006, Virology.

[18]  R. Belshe,et al.  Genomic Analysis of Vaccine-Derived Poliovirus Strains in Stool Specimens by Combination of Full-Length PCR and Oligonucleotide Microarray Hybridization , 2005, Journal of Clinical Microbiology.

[19]  D. Stone,et al.  The 5' noncoding region and virulence of poliovirus vaccine strains. , 1994, Trends in microbiology.

[20]  D. Stone,et al.  Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. , 1992, Virology.